Skip to content

Robin Carhart-Harris

Imperial College London, Multidisciplinary Association for Psychedelic Studies

312 papers in the library · 30,055 citations · publishing 2007-2026

Papers

Sort Most recent Most cited

Mental health outcomes following a psilocybin session within Oregon’s state-regulated model: A naturalistic study

medRxiv February 19, 2026 Amanda Gow, Emily Shih, Ryan Reid et al. preprint

Abstract Background In 2020, Oregon became the first U.S. state to establish a regulated framework for adults to access psilocybin services using naturally-derived mushroom products. No studies have examined mental health outcomes among individuals receiving psilocybin in this context. Aims To evaluate changes in self-reported symptoms of depression, anxiety, and well-being 30-days...

A short-acting psychedelic intervention for major depressive disorder: a phase IIa randomized placebo-controlled trial.

Nature Medicine February 16, 2026 David Erritzøe, Tommaso Barba, Tiffanie Benway et al. 4 citations

Major depressive disorder (MDD) is a leading cause of disability worldwide, yet many patients have inadequate responses to current treatments. Dimethyltryptamine (DMT), a serotonergic psychedelic with rapid onset and short duration, shows promise as a potential antidepressant (AD), although clinical evidence in MDD remains limited. We conducted a phase IIa, double-blind, placebo-controlled,...

The science of psychedelic medicine.

Nature Medicine February 6, 2026 Joshua S. Siegel, Conor Liston, Ginger E. Nicol et al. 10 citations

Classic psychedelics typically act at the serotonin 5-HT2A receptor to profoundly alter brain function and consciousness. Research on these compounds has accelerated. Major strides have been made in understanding their unique mechanisms of action and clinical potential. This Review outlines the state of psychedelic science, spanning cellular mechanisms, systems neuroscience and clinical...

LSD Reconfigures Cortical Dynamics Through Faster Brain Rhythms and Increased Fractal Dimension

bioRxiv (Cold Spring Harbor Laboratory) January 29, 2026 Venkatesh Subramani, Timothy Nest, Annalisa Pascarella et al. 1 citation preprint

Abstract Lysergic acid diethylamide (LSD) profoundly alters conscious experience, yet the electrophysiological mechanisms by which it reshapes neural dynamics remain incompletely understood. A hallmark of psychedelic states is widespread cortical desynchronization, typically inferred from reductions in spectral power, but whether such effects reflect genuine weakening of neural oscillations or...

DOI: 10.64898/2026.01.28.702361 (opens in new tab) Magnetoencephalography Aperiodic graph Rhythm Electrophysiology +11

Blunted Psychedelic Drug Effects in Older Adults

American Journal of Geriatric Psychiatry 2026 Jacob S. Aday, Robin Carhart-Harris, Kevin F. Boehnke 2 citations

Classic psychedelic drugs, including psilocybin, lysergic acid diethylamide, and ayahuasca/N,N-dimethyltryptamine, are increasingly being studied as therapeutics for myriad health conditions; however, predicting individual responses is notoriously difficult. An arguably underappreciated variable potentially moderating responses to psychedelics is age. Older adults exhibit unique pathogenesis of...

Brain Dynamics of Classical Psychedelics Show Paradoxical Hierarchical Flattening With Increased Complexity

SSRN Electronic Journal 2026 Jakub Vohryzek, Elvira Garcia Guzman, Morten L. Kringelbach et al. 1 citation preprint

Despite divergent behavioral and phenomenological profiles, both psychedelic states and reduced states of consciousness have been associated with a flattening of the brain's functional hierarchy. To address this apparent paradox, we developed a more specific definition of hierarchy based on the proximity of the brain to thermodynamic equilibrium and then applied it to investigate the changes to...

DOI: 10.2139/ssrn.6137001 (opens in new tab) Full text (opens in new tab) Flattening Consciousness Hierarchy Complement music +11

Computational spirits: a neuroscientific account of psychedelic entity encounters.

Neuroscience of Consciousness 2026 Jonas Mago, George Deane, Lars Sandved-Smith et al.

Under the influence of psychedelics, people often report encountering "entities" who seem to have their own autonomous agency. Depending on the cultural milieu, these entities are reported to take a variety of forms, including spirits, elves, ancestors, or fragments of the self. Encounters with such beings hold a central place in many traditions of psychedelic practice around the world. And...

Micro-phenomenology of immersion and perceived presences under DMT.

Neuroscience of Consciousness 2026 James W. Sanders, Raphaël Millière, Ema Demšar et al.

Psychedelic compound N,N-Dimethyltryptamine (DMT) is renowned for inducing highly immersive experiences, often including encounters with seemingly sentient presences. While such phenomena are well documented, immersion under psychedelics remains conceptually underdefined and phenomenologically underexplored. Here we apply micro-phenomenology to characterize immersion under DMT as a structured...

DOI: 10.1093/nc/niag015 (opens in new tab) Full text (opens in new tab) DMT Immersion Micro-phenomenology Multisensory integration +3

Ceremonial Psychedelic Experiences and Changes in Mental Health Outcomes in Those with Adverse Childhood Experiences

Psychedelic Medicine December 15, 2025 M. Mehmood, Rebecka Bremler, M. Spriggs et al.

Background:Adverse childhood experiences (ACEs) are known to contribute to mental health issues and interfere with response to mental health interventions. Psychedelics have been found to improve mental health outcomes; however, the exploration of the effects of psychedelics on mental health in those with higher ACEs remains limited. The present study aimed to examine mental health outcomes and...

The entropic brain today

Brain December 12, 2025 Robin Carhart-Harris 2 citations

Introduced in 2014 and revised in 2018, the entropic brain hypothesis has accrued a wealth of supportive evidence. The hypothesis states that-along a dimension of the size of phenomenal consciousness-expansive states reliably exhibit increased brain entropy whereas the inverse applies for states of no or reduced consciousness. Examples of expansive states include expert meditation, flicker...

Defining ‘psychedelic’

December 4, 2025 Avery Ostrand, Matthew M. Nour, Christopher Timmermann et al. 2 citations preprint

Humphry Osmond coined the term ‘psychedelic’ in 1956, conjoining ‘psyche’ for ‘soul’ and ‘delic’ from ‘dêlos’ for ‘to manifest’ or ‘illuminate.’ Soul-illumination is an adjective that describes a psychological state or process. However, Osmond’s intention was to use the adjective to name— not just a state— but a category of drug that can induce the subjective effect as its principal action;...

Correction: Short- and long-term modulation of rat prefrontal cortical activity following single doses of psilocybin.

Molecular Psychiatry December 1, 2025 Ross J. Purple, Rahul Gupta, Christopher W. Thomas et al. correction

In this article the author’s name Robin Carhart-Harris was incorrectly written as Robin Carhartt-Harris. The original article has been corrected.

A Mesoscale Framework for Psychedelic Drug Action in the Human Brain

bioRxiv November 26, 2025 Rui Dai, Rodrigo Cofré, Christopher Timmermann et al. preprint

The mechanism of psychedelic drug action is a dynamic area of neuroscience, with two major lines of investigation: (1) laboratory studies at the molecular and cellular level, and (2) human neuroimaging studies of functional brain networks. Despite considerable progress, there remains insufficient understanding of the link between molecular/cellular substrates of psychedelics and the whole-brain...

DMT-induced shifts in criticality correlate with self-dissolution.

Journal of Neuroscience November 24, 2025 Mona Irrmischer, Marco Aqil, Lisa Luan et al.

Psychedelics profoundly alter subjective experience and brain dynamics. Brain oscillations express signatures of near-critical dynamics, relevant for healthy function. Alterations in the proximity to criticality have been suggested to underlie the experiential and neurological effects of psychedelics. Here, we investigate the effects of a psychedelic substance (DMT) on the criticality of brain...

Complexity as a Potential Neurophysiological Correlate of Awe

bioRxiv (Cold Spring Harbor Laboratory) November 21, 2025 Joseph C. C. Chen, Gabriella Mace, Avery Ostrand et al. preprint

Abstract Awe is a positive emotion often accompanied by sensations of vastness and unity, with known benefits for well-being and social behavior. However, its neural underpinnings remain poorly understood. We recorded electroencephalography (EEG) and autonomic physiology in 23 healthy older participants while they watched a nature-based audiovisual film and subjectively rated awe events. Awe...

DOI: 10.1101/2025.11.20.689403 (opens in new tab) Electroencephalography Neurophysiology Neural activity Spectral analysis +4

A Virtual Clinical Trial of Psychedelics to Treat Patients With Disorders of Consciousness

Advanced Science November 20, 2025 Paolo Cardone, Charlotte Martial, Yonatan Sanz Perl et al. 3 citations

Abstract Disorders of consciousness (DoC), including unresponsive wakefulness syndrome (UWS) and minimally conscious state (MCS), have limited treatment options and are characterized by low complexity of brain activity. Recent research suggests that psychedelic drugs, which enhance the complexity of brain activity, could offer promising therapies. Here, individualized whole‐brain computational...

DOI: 10.1002/advs.202511780 (opens in new tab) Full text (opens in new tab) Psilocybin Persistent vegetative state Wakefulness Minimally conscious state +6

Correction: Synergistic, multi-level understanding of psychedelics: three systematic reviews and meta-analyses of their pharmacology, neuroimaging and phenomenology.

Translational Psychiatry November 13, 2025 Kenneth Shinozuka, Katarina Jerotic, Pedro A. M. Mediano et al. correction

The meta-analysis of the 11-dimensional Altered States of Consciousness (11D-ASC) included three studies that contained duplicated data from other papers: Duerler et al. (2021), Lewis et al. (2017), and Preller et al. (2017). When these studies are removed from the analysis, the results are generally similar to the previously reported findings. Out of 33 comparisons (3 doses x 11 dimensions)...

DOI: 10.1038/s41398-025-03731-7 (opens in new tab) Full text (opens in new tab) Psychedelics Brain activity Consciousness Mental well-being

Negative affective bias in depression following treatment with psilocybin or escitalopram – a secondary analysis from a randomized trial

Translational Psychiatry November 13, 2025 Bruna Giribaldi Cunha, David Nutt, Marieke Martens et al.

Abstract Recent clinical trial data suggests that ratings on depression scales are lowered after psilocybin therapy compared to placebo, though it is unclear what neuropsychological mechanisms underpin these effects. This study compared psilocybin, with an established antidepressant, escitalopram, to investigate whether there are shared or distinct effects on emotional information processing....

Efficacy, all-cause discontinuation, and safety of serotonergic psychedelics and MDMA to treat mental disorders: A living systematic review with meta-analysis.

European Neuropsychopharmacology November 7, 2025 Mikkel Højlund, Helin Y. Kafali, Begüm Kırmızı et al. 12 citations

Serotonergic psychedelics and 3,4-methylendioxtmethamphetamine (MDMA) are promising treatments for mental disorders with a continuously evolving evidence base. We searched Pubmed/Scopus/clinical trial registries up to 08july2025 for double-blind randomized controlled trials (RCTs) testing MDMA or serotonergic psychedelics in patients with mental disorders. Primary outcomes were change in...

DOI: 10.1016/j.euroneuro.2025.09.011 (opens in new tab) Psychedelic therapy MDMA Therapy Psychedelic medicine Entheogenic therapy +12

Exploring the potential psychological predictors associated with changes in depression, anxiety, and well-being following naturalistic psychedelic use.

Journal of Psychiatric Research November 1, 2025 Felipe Herrmann, Grant Jones, Daniel M Low et al.

Although research shows that psychedelic use may lead to improvement in mental health and well-being, the underlying changes in psychological predictors associated with these improvements remain unclear. 161 participants were recruited in a prospective online survey assessing naturalistic psychedelic use. We used lasso regression to assess how 19 distinct changes in psychological variables...

Dissociable effects of LSD and MDMA on striato-cortical connectivity in healthy subjects.

Neuropsychopharmacology October 31, 2025 Natalie Ertl, Imran Ashraf, Lisa Azizi et al. 1 citation

Lysergic acid diethylamide (LSD) and 3,4-Methylenedioxymethamphetamine (MDMA) are widely used psychoactive drugs and their potential use in psychiatric medicine is currently generating interest. The mechanism by which these drugs may assist recovery in various disorders such as addiction and post-traumatic stress disorder (PTSD) is still not well understood. Most investigations of the effects...

DOI: 10.1038/s41386-025-02270-5 (opens in new tab) MDMA Psychedelics: LSD Compounds Areas controlling thought +9

Eigenmodes of the deep unconscious: the neuropsychology of Jungian archetypes and psychedelic experience.

Neuroscience of Consciousness October 18, 2025 Hugh McGovern, Marco Aqil, Selen Atasoy et al. 4 citations

This article presents a neuroscientific interpretation of Carl Jung's theory of archetypes and their experience in altered states of consciousness. We begin by rehearsing the Free Energy Principle and Predictive Processing as foundational frameworks that subserve and inform the thesis that follows. The following sections examine three aspects of archetypes: the affective core rooted in...

DOI: 10.1093/nc/niaf039 (opens in new tab) Full text (opens in new tab) Psychedelics Psychedelic experience Altered states Consciousness expansion +15

Cross-species mapping of psychedelic gene expression reveals links to the 5HT2A receptor, cortical layers, and human accelerated regions

Research Square October 3, 2025 Patrick A. McConnell, Jackson Raffety, Andrew Li et al. preprint

Abstract Psychedelic drugs exert rapid and profound effects on human consciousness and are increasingly explored for their clinical potential. Yet, the genetic programs through which psychedelics reshape brain function and structure remain incompletely understood, in part because most studies have been conducted in preclinical models and cell cultures. We conducted a systematic literature...

DOI: 10.21203/rs.3.rs-7625999/v1 (opens in new tab) Psychedelics Compounds Psychedelic action Gene expression +10

N,N-dimethyltryptamine effects on connectome harmonics, subjective experience and comparative psychedelic experiences.

Neuropsychopharmacology September 12, 2025 Jakub Vohryzek, Andrea I. Luppi, Selen Atasoy et al. 2 citations

Exploring the intricate relationship between brain's structure and function, and how this affects subjective experience is a fundamental pursuit in neuroscience. Psychedelic substances offer a unique insight into the influences of specific neurotransmitter systems on perception, cognition and consciousness. Specifically, their impact on brain function propagates across the structural connectome...

A lexicon for psychedelic research and treatment

Drug Science, Policy and Law September 1, 2025 David Nutt, David Erritzøe, Anne Katrin Schlag et al. 9 citations

Psychedelics are undergoing a clinical research renaissance, with compounds such as psilocybin advancing to Phase 3 trials for treatment-resistant depression and receiving fast-track or breakthrough designations from regulatory agencies. Despite this progress, the field lacks standardized terminology to guide clinical development, dosing, safety monitoring, and regulatory classification. Here,...